2025年第三季度，诺和诺德的核心产品Wegovy®销售额同比狂飙54%，但公司随之而来的决定却让很多人吃了一惊：全球裁员9000人。一边是王牌药物的爆发式增长，一边是大刀阔斧的战略收缩。图：2025年Q3财务报告Wegovy®的现金牛地位毋庸置疑，但资本市场已在追问，诺和诺德的“下一个Wegovy®”在哪里？截至12月10日收盘，诺和诺德股价报收于49.05美元，较前一日上涨5.8%，市值重回...
Source Link2025年第三季度，诺和诺德的核心产品Wegovy®销售额同比狂飙54%，但公司随之而来的决定却让很多人吃了一惊：全球裁员9000人。一边是王牌药物的爆发式增长，一边是大刀阔斧的战略收缩。图：2025年Q3财务报告Wegovy®的现金牛地位毋庸置疑，但资本市场已在追问，诺和诺德的“下一个Wegovy®”在哪里？截至12月10日收盘，诺和诺德股价报收于49.05美元，较前一日上涨5.8%，市值重回...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.